The recently released ANNEXa-I study is one of the most anticipated and subsequently talked about clinical trials in some time. And this is Part 2 in the 2-part episode series deep diving into the details of this trial researching Andexanet alfa in ICH.
Continuing to help answer so many of the remaining questions, I’m joined by Scott Dietrich, Brian Gilbert, and Todd Miano. Part 2 (this episode) will discuss safety/thrombotic findings followed by practical considerations/applications.
The episode starts off with a discussion on safety. Is there a mechanism that explains this increased thrombosis risk? What is the role of VTE prophylaxis? Are these thrombotic rates similar to other Andexanet alfa studies? How do we safely use in surgical patients?
Before we get into our practical application and use of Andexanet alfa. How to interpret observational data in the wake of ANNEXA-I? Any considerations with storage/reconstitution? Are there lab assays available to confirm presence of Factor Xa inhibitor anticoagulant? What is our “elevator pitch” to a P&T committee and so much more!
Reminder: Part 1, focusing on efficacy/statistics, in this series is available now
ANNEXa-I rapid reaction episode also available
YouTube video combining Parts I and II is also ready to watch
Pharmacy to Dose: The Critical Care Podcast 
Leave a comment